–Investigator’s Retrospective Analysis Published in the Journal of Urology Provides Protocol for Antegrade Administration of Jelmyto, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer–
Reno, Nevada (UroToday.com) — UroGen Pharma Ltd., a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, announced the first published report of real-world experience utilizing the antegrade approach for Jelmyto® (mitomycin) for pyelocalyceal solution administration in the Journal of Urology online on February 7, 2022. This report provides a stepwise treatment approach to low-grade Upper Tract Urothelial Cancer (LG UTUC) from initial ureteroscopy to nephrostomy placement, Jelmyto administration, and eventual nephrostomy removal.